367 related articles for article (PubMed ID: 27856823)
1. Mepolizumab in the management of severe eosinophilic asthma in adults: current evidence and practical experience.
Varricchi G; Bagnasco D; Ferrando M; Puggioni F; Passalacqua G; Canonica GW
Ther Adv Respir Dis; 2017 Jan; 11(1):40-45. PubMed ID: 27856823
[TBL] [Abstract][Full Text] [Related]
2. Evidence for the efficacy and safety of anti-interleukin-5 treatment in the management of refractory eosinophilic asthma.
Hilvering B; Xue L; Pavord ID
Ther Adv Respir Dis; 2015 Aug; 9(4):135-45. PubMed ID: 25900924
[TBL] [Abstract][Full Text] [Related]
3. Essential Mechanisms of Differential Activation of Eosinophils by IL-3 Compared to GM-CSF and IL-5.
Esnault S; Kelly EA
Crit Rev Immunol; 2016; 36(5):429-444. PubMed ID: 28605348
[TBL] [Abstract][Full Text] [Related]
4. Benralizumab: A New Approach for the Treatment of Severe Eosinophilic Asthma.
Dávila González I; Moreno Benítez F; Quirce S
J Investig Allergol Clin Immunol; 2019 Apr; 29(2):84-93. PubMed ID: 31017107
[TBL] [Abstract][Full Text] [Related]
5. Allergic diseases: From bench to clinic - Contribution of the discovery of interleukin-5.
Yanagibashi T; Satoh M; Nagai Y; Koike M; Takatsu K
Cytokine; 2017 Oct; 98():59-70. PubMed ID: 28863833
[TBL] [Abstract][Full Text] [Related]
6. Expression of eosinophil β chain-signaling cytokines receptors, outer-membrane integrins, and type 2 inflammation biomarkers in severe non-allergic eosinophilic asthma.
Kalinauskaite-Zukauske V; Januskevicius A; Janulaityte I; Miliauskas S; Malakauskas K
BMC Pulm Med; 2019 Aug; 19(1):158. PubMed ID: 31438916
[TBL] [Abstract][Full Text] [Related]
7. Mepolizumab in the treatment of severe eosinophilic asthma.
Fainardi V; Pisi G; Chetta A
Immunotherapy; 2016; 8(1):27-34. PubMed ID: 26653083
[TBL] [Abstract][Full Text] [Related]
8. New approaches in the treatment of asthma.
Ramshaw HS; Woodcock JM; Bagley CJ; McClure BJ; Hercus TR; Lopez AF
Immunol Cell Biol; 2001 Apr; 79(2):154-9. PubMed ID: 11264710
[TBL] [Abstract][Full Text] [Related]
9. Mepolizumab for eosinophilic severe asthma: recent studies.
Robinson DS; Kariyawasam HH
Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
[TBL] [Abstract][Full Text] [Related]
10. IL-3 Maintains Activation of the p90S6K/RPS6 Pathway and Increases Translation in Human Eosinophils.
Esnault S; Kelly EA; Shen ZJ; Johansson MW; Malter JS; Jarjour NN
J Immunol; 2015 Sep; 195(6):2529-39. PubMed ID: 26276876
[TBL] [Abstract][Full Text] [Related]
11. Relative contributions of human types 1 and 2 T-helper cell-derived eosinophilotrophic cytokines to development of eosinophilia.
Wierenga EA; Backx B; Snoek M; Koenderman L; Kapsenberg ML
Blood; 1993 Sep; 82(5):1471-9. PubMed ID: 8364199
[TBL] [Abstract][Full Text] [Related]
12. CSL311, a novel, potent, therapeutic monoclonal antibody for the treatment of diseases mediated by the common β chain of the IL-3, GM-CSF and IL-5 receptors.
Panousis C; Dhagat U; Edwards KM; Rayzman V; Hardy MP; Braley H; Gauvreau GM; Hercus TR; Smith S; Sehmi R; McMillan L; Dottore M; McClure BJ; Fabri LJ; Vairo G; Lopez AF; Parker MW; Nash AD; Wilson NJ; Wilson MJ; Owczarek CM
MAbs; 2016; 8(3):436-53. PubMed ID: 26651396
[TBL] [Abstract][Full Text] [Related]
13. IL-3, IL-5, granulocyte-macrophage colony-stimulating factor receptor alpha-subunit, and common beta-subunit expression by peripheral leukocytes and blood dendritic cells.
Yamada T; Sun Q; Zeibecoglou K; Bungre J; North J; Kay AB; Lopez AF; Robinson DS
J Allergy Clin Immunol; 1998 May; 101(5):677-82. PubMed ID: 9600506
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab for the treatment of severe eosinophilic asthma.
Poulakos MN; Cargill SM; Waineo MF; Wolford AL
Am J Health Syst Pharm; 2017 Jul; 74(13):963-969. PubMed ID: 28645995
[TBL] [Abstract][Full Text] [Related]
15. Interleukin-5 pathway inhibition in the treatment of eosinophilic respiratory disorders: evidence and unmet needs.
Varricchi G; Bagnasco D; Borriello F; Heffler E; Canonica GW
Curr Opin Allergy Clin Immunol; 2016 Apr; 16(2):186-200. PubMed ID: 26859368
[TBL] [Abstract][Full Text] [Related]
16. Severe eosinophilic asthma: from the pathogenic role of interleukin-5 to the therapeutic action of mepolizumab.
Pelaia C; Vatrella A; Busceti MT; Gallelli L; Terracciano R; Savino R; Pelaia G
Drug Des Devel Ther; 2017; 11():3137-3144. PubMed ID: 29133975
[TBL] [Abstract][Full Text] [Related]
17. Delayed eosinophil apoptosis in asthma.
Kankaanranta H; Lindsay MA; Giembycz MA; Zhang X; Moilanen E; Barnes PJ
J Allergy Clin Immunol; 2000 Jul; 106(1 Pt 1):77-83. PubMed ID: 10887309
[TBL] [Abstract][Full Text] [Related]
18. Peripheral blood CD4 but not CD8 t-lymphocytes in patients with exacerbation of asthma transcribe and translate messenger RNA encoding cytokines which prolong eosinophil survival in the context of a Th2-type pattern: effect of glucocorticoid therapy.
Corrigan CJ; Hamid Q; North J; Barkans J; Moqbel R; Durham S; Gemou-Engesaeth V; Kay AB
Am J Respir Cell Mol Biol; 1995 May; 12(5):567-78. PubMed ID: 7742019
[TBL] [Abstract][Full Text] [Related]
19. Engineering of Humanized Antibodies Against Human Interleukin 5 Receptor Alpha Subunit That Cause Potent Antibody-Dependent Cell-Mediated Cytotoxicity.
Kim JE; Lee DH; Jung K; Kim EJ; Choi Y; Park HS; Kim YS
Front Immunol; 2020; 11():593748. PubMed ID: 33488590
[TBL] [Abstract][Full Text] [Related]
20. Mepolizumab: First Global Approval.
Keating GM
Drugs; 2015 Dec; 75(18):2163-9. PubMed ID: 26603873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
